Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Arix Bioscience plc
  6. News
  7. Summary
    ARIX   GB00BD045071

ARIX BIOSCIENCE PLC

(ARIX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Arix Bioscience : To Invest $11 Million In Disc Medicine

09/02/2021 | 07:15am EST


ę MT Newswires 2021
All news about ARIX BIOSCIENCE PLC
11/08Arix Bioscience Unit Autolus Partners With Blackstone To Develop Cancer Therapies
MT
10/29Arix Bioscience's Portfolio Firm Aura Biosciences Prices Nasdaq IPO
MT
10/18ARIX BIOSCIENCE : Cancels Share Repurchase Program to Focus on Investments
MT
10/18Tranche Update on Arix Bioscience plc's Equity Buyback Plan announced on March 15, 2021..
CI
10/18Arix Bioscience plc's Equity Buyback announced on March 15, 2021, has expired with 6,42..
CI
10/12ARIX BIOSCIENCE : Investee Aura Biosciences Posts Interim Data from Choroidal Melanoma Dru..
MT
10/08ARIX BIOSCIENCE : Investee Pyxis Oncology Raises $167.2 Million in US IPO
MT
10/06FTSE 100 Closes Down on Fears of Rising Consumer Costs
DJ
10/06FTSE Drops, Sterling Expected to Gain on Prospect of Rate Rise
DJ
10/06ARIX BIOSCIENCE : Makes Interim CEO Permanent
MT
More news
Financials
Sales 2021 - - -
Net income 2021 - - -
Net cash 2021 133 M 176 M 176 M
P/E ratio 2021 -
Yield 2021 -
Capitalization 159 M 210 M 210 M
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 12
Free-Float 72,0%
Chart ARIX BIOSCIENCE PLC
Duration : Period :
Arix Bioscience plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARIX BIOSCIENCE PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 128,00 GBX
Average target price 256,00 GBX
Spread / Average Target 100%
EPS Revisions
Managers and Directors
Robert William Henry Lyne CEO, COO, Secretary, Director & General Counsel
Marcus Karia Group Finance Director
Peregrine D. E. M. Moncreiffe Non-Executive Chairman
Graeme Smith Chief Technology Officer
Michael William Bunbury Senior Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ARIX BIOSCIENCE PLC-41.55%210
INVESTOR AB (PUBL)48.49%71 936
CK HUTCHISON HOLDINGS LIMITED-7.67%24 582
GROUPE BRUXELLES LAMBERT SA16.09%16 182
HAL TRUST23.63%13 757
AB INDUSTRIVÄRDEN (PUBL)-1.24%12 689